Bookmark and Share
CYM51010 (CID 23723457) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(16)
 
 
Inactive(527)
 
 
Inconclusive(7)
 
 
Unspecified(1)
 
 
Top Targets:
7TM GPCR Srx(31)
 
 
 
TRP 2(20)
 
 
 
7TM GPCR Srsx(15)
 
 
CAP ED(5)
 
 
Troponin(4)
 
 
BioAssay Types:
Screening(379)
 
 
 
Confirmatory(166)
 
 
 
 
 
Literature(2)
 
 
BioActivity Types:
Potency(118)
 
 
 
 
 
IC50(28)
 
 
EC50(17)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 505    Data Row: 551   Total Pages: 28   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID47197229]
EC50 0.0267Confirmation dose response assay for compounds that activate transient receptor potential cation channel C4 (TRPC4) [AID434937, Type: confirmatory]alternatively spliced Trp4 [Mus musculus] [gi:2935630]
View
2
[SID47197229]
EC50 0.22694Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID588407, Type: confirmatory]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
3
[SID47197229]
EC50 0.22694Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID588407, Type: confirmatory]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
4
[SID134220670]
EC50 0.403Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
5
[SID134220670]
EC50 0.403Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay [AID651685, Type: confirmatory]opioid receptor, delta 1 [Homo sapiens] [gi:119628077]
View
6
[SID134220670]
EC50 1.1Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreen [AID651686, Type: confirmatory]opioid receptor, delta 1 [Homo sapiens] [gi:119628077]
View
7
[SID47197229]
Potency 4.1475Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation [AID504834, Type: confirmatory]
View
8
[SID47197229]
EC50 4.502Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRD1 homodimerization [AID588411, Type: confirmatory]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
9
[SID47197229]
Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504904, Type: screening]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
10
[SID47197229]
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504326, Type: screening]mu-type opioid receptor isoform MOR-1 [Homo sapiens] [gi:117940060]
View
11
[SID47197229]
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504326, Type: screening]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
12
[SID47197229]
Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors [AID504904, Type: screening]delta-type opioid receptor [Homo sapiens] [gi:63477962]
View
13
[SID47197229]
Specificity screen against TRPC6 for compounds that activate transient receptor potential cation channel C4 (TRPC4) [AID434950, Type: screening]short transient receptor potential channel 6 isoform 1 [Mus musculus] [gi:160333370]
View
14
[SID47197229]
Confirmatory screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4) [AID2426, Type: screening]alternatively spliced Trp4 [Mus musculus] [gi:2935630]
View
15
[SID47197229]
Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4). [AID2237, Type: screening]alternatively spliced Trp4 [Mus musculus] [gi:2935630]
View
16
[SID47197229]
Second confirmatory screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4) [AID2461, Type: screening]alternatively spliced Trp4 [Mus musculus] [gi:2935630]
View
17
[SID47197229]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
18
[SID47197229]
Potency 5.6234qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS [AID624287, Type: confirmatory]Guanine nucleotide-binding protein G(s) subunit alpha isoforms short [gi:52000961]
View
19
[SID134220670]
CC50 10Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response counterscreen assay to determine cytotoxicity of test compounds [AID651904, Type: confirmatory]
View
20
[SID47197229]
Potency 12.5893qHTS of PTHR Inhibitors: Primary Screen [AID743266, Type: confirmatory]parathyroid hormone/parathyroid hormone-related peptide receptor precursor [Homo sapiens] [gi:296080761]
View